Dallas-based biotech company Opexa Therapeutics, Inc. has just announced that they have been included in the list of “Top Projects to Watch” by Elsevier Business Intelligence. The company’s president and CEO , Neil K. Warma, will be presenting an overview of the company at the Therapeutic Area Partnerships meeting which is set to begin next week, November 18, at the Hyatt Regency in Boston until November 20. Warma is scheduled to present the company overview on Tuesday, November 19 at 2:55 p.m.
According to David Cassak of Elsevier Business Intelligence, the listed companies were selected according to a stringent set of criteria and have been judged to stand for what the committee deems qualified as some of the most promising in the industry. The criteria are as follows:
- Unmet medical need
- Market potential
- Diversity of indications
- Strong science
- Multi-level partnering opportunities
- Potential for new opportunities beyond initial indications and corporate stability
Warma shared that the company is honored to have been included in such an esteemed group and is pleased to attribute the recognition to their significant contributions to the field of Precision Immunotherapy through their patented T-cell technology against multiple sclerosis.